New hope for aHUS patients: Long-Term iptacopan study launches
NCT ID NCT05795140
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the long-term safety and effectiveness of the drug iptacopan in people with a rare blood disorder called atypical hemolytic uremic syndrome (aHUS). Participants must have completed a previous iptacopan study and still benefit from the drug. The goal is to monitor side effects and see if the drug continues to control the disease over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGSão Paulo, São Paulo, 05403 000, Brazil
-
Novartis Investigative Site
RECRUITINGRio de Janeiro, 22270-060, Brazil
-
Novartis Investigative Site
RECRUITINGBeijing, 100034, China
-
Novartis Investigative Site
RECRUITINGOstrava, Poruba, 708 52, Czechia
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGNagpur, Maharashtra, 440015, India
-
Novartis Investigative Site
RECRUITINGPune, Maharashtra, 411011, India
-
Novartis Investigative Site
RECRUITINGIruma-gun, Saitama, 3500495, Japan
-
Novartis Investigative Site
RECRUITINGAnkara, Yenimahalle, 06500, Turkey (Türkiye)
-
Novartis Investigative Site
RECRUITINGMersin, Yenisehir, 33110, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Skin biopsies could unlock hidden genetic diagnoses
- Real-World study tracks Ravulizumab's impact on rare kidney disease
- New pill shows promise for rare blood disorder aHUS
- New drug ravulizumab aims to control rare blood disorder aHUS
- Promising aHUS drug trial stalls after only 6 patients enrolled
- New hope for kids with rare kidney disease: crovalimab trial underway